Impacto del diagnóstico de cáncer de pulmón en los costos del sistema de salud en Colombia: comparación de tres métodos de estimación basados en puntajes de propensión

Ilustraciones, diagramas, mapas

Autores:
Amaya Nieto, Javier Antonio
Tipo de recurso:
Fecha de publicación:
2022
Institución:
Universidad Nacional de Colombia
Repositorio:
Universidad Nacional de Colombia
Idioma:
spa
OAI Identifier:
oai:repositorio.unal.edu.co:unal/86518
Acceso en línea:
https://repositorio.unal.edu.co/handle/unal/86518
https://repositorio.unal.edu.co/
Palabra clave:
610 - Medicina y salud
Neoplasias Pulmonares
Sistemas de Salud
Lung Neoplasms
Health Systems
Costos de la salud
Cáncer de pulmón
Puntaje de propensión
Costo incremental
Lung Cancer
Propensity Score
Incremental Cost of Illness
Rights
openAccess
License
Atribución-NoComercial-SinDerivadas 4.0 Internacional
id UNACIONAL2_f3445e81593540b2d45d241a17d894ef
oai_identifier_str oai:repositorio.unal.edu.co:unal/86518
network_acronym_str UNACIONAL2
network_name_str Universidad Nacional de Colombia
repository_id_str
dc.title.spa.fl_str_mv Impacto del diagnóstico de cáncer de pulmón en los costos del sistema de salud en Colombia: comparación de tres métodos de estimación basados en puntajes de propensión
dc.title.translated.eng.fl_str_mv Impact of Lung Cancer Diagnosis on Health System Costs in Colombia: Comparison of Three Estimation Methods Based on Propensity Scores
title Impacto del diagnóstico de cáncer de pulmón en los costos del sistema de salud en Colombia: comparación de tres métodos de estimación basados en puntajes de propensión
spellingShingle Impacto del diagnóstico de cáncer de pulmón en los costos del sistema de salud en Colombia: comparación de tres métodos de estimación basados en puntajes de propensión
610 - Medicina y salud
Neoplasias Pulmonares
Sistemas de Salud
Lung Neoplasms
Health Systems
Costos de la salud
Cáncer de pulmón
Puntaje de propensión
Costo incremental
Lung Cancer
Propensity Score
Incremental Cost of Illness
title_short Impacto del diagnóstico de cáncer de pulmón en los costos del sistema de salud en Colombia: comparación de tres métodos de estimación basados en puntajes de propensión
title_full Impacto del diagnóstico de cáncer de pulmón en los costos del sistema de salud en Colombia: comparación de tres métodos de estimación basados en puntajes de propensión
title_fullStr Impacto del diagnóstico de cáncer de pulmón en los costos del sistema de salud en Colombia: comparación de tres métodos de estimación basados en puntajes de propensión
title_full_unstemmed Impacto del diagnóstico de cáncer de pulmón en los costos del sistema de salud en Colombia: comparación de tres métodos de estimación basados en puntajes de propensión
title_sort Impacto del diagnóstico de cáncer de pulmón en los costos del sistema de salud en Colombia: comparación de tres métodos de estimación basados en puntajes de propensión
dc.creator.fl_str_mv Amaya Nieto, Javier Antonio
dc.contributor.advisor.none.fl_str_mv Buitrago Gutiérrez, Giancarlo
dc.contributor.author.none.fl_str_mv Amaya Nieto, Javier Antonio
dc.contributor.researchgroup.spa.fl_str_mv Servicios y sistemas de salud
dc.contributor.orcid.spa.fl_str_mv Amaya Nieto, Javier Antonio [000-0002-9856-6242]
dc.contributor.researchgate.spa.fl_str_mv https://www.researchgate.net/profile/Javier-Amaya-Nieto
dc.contributor.googlescholar.spa.fl_str_mv Amaya Nieto, Javier Antonio [a0ZnRskAAAAJ&hl]
dc.subject.ddc.spa.fl_str_mv 610 - Medicina y salud
topic 610 - Medicina y salud
Neoplasias Pulmonares
Sistemas de Salud
Lung Neoplasms
Health Systems
Costos de la salud
Cáncer de pulmón
Puntaje de propensión
Costo incremental
Lung Cancer
Propensity Score
Incremental Cost of Illness
dc.subject.other.spa.fl_str_mv Neoplasias Pulmonares
Sistemas de Salud
dc.subject.other.eng.fl_str_mv Lung Neoplasms
Health Systems
dc.subject.lemb.spa.fl_str_mv Costos de la salud
dc.subject.proposal.spa.fl_str_mv Cáncer de pulmón
Puntaje de propensión
Costo incremental
dc.subject.proposal.eng.fl_str_mv Lung Cancer
Propensity Score
Incremental Cost of Illness
description Ilustraciones, diagramas, mapas
publishDate 2022
dc.date.issued.none.fl_str_mv 2022
dc.date.accessioned.none.fl_str_mv 2024-07-17T14:35:44Z
dc.date.available.none.fl_str_mv 2024-07-17T14:35:44Z
dc.type.spa.fl_str_mv Trabajo de grado - Maestría
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/masterThesis
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
dc.type.content.spa.fl_str_mv Text
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/TM
status_str acceptedVersion
dc.identifier.uri.none.fl_str_mv https://repositorio.unal.edu.co/handle/unal/86518
dc.identifier.instname.spa.fl_str_mv Universidad Nacional de Colombia
dc.identifier.reponame.spa.fl_str_mv Repositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourl.spa.fl_str_mv https://repositorio.unal.edu.co/
url https://repositorio.unal.edu.co/handle/unal/86518
https://repositorio.unal.edu.co/
identifier_str_mv Universidad Nacional de Colombia
Repositorio Institucional Universidad Nacional de Colombia
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.references.spa.fl_str_mv 1. Goss PE, Lee BL, Badovinac-Crnjevic T, et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013;14:391-436. doi:10.1016/s1470-2045(13)70048-2
2. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a populationbased study. Lancet Oncol. 2012;13(8):790-801. doi:https://doi.org/10.1016/S1470-2045(12)70211-5
3. Sierra MS, Soerjomataram I, Antoni S, et al. Cancer patterns and trends in Central and South America. Cancer Epidemiol. 2016;44:S23-S42. doi:10.1016/j.canep.2016.07.013
4. Gilchrist SC, Howard VJ, Akinyemiju T, et al. Association of Sedentary Behavior with Cancer Mortality in Middle-aged and Older US Adults. JAMA Oncol. 2020;6(8):1210-1217. doi:10.1001/jamaoncol.2020.2045
5. Weintraub WS. The Economic Burden of Illness. JAMA Netw Open. 2023;6(3):e232663-e232663. doi:10.1001/jamanetworkopen.2023.2663
6. Organization IA for R on C-WH. Global Cancer Observatory. 2020. https://gco.iarc.fr/.
7. Mohar A, Bargalló E, Ramírez MT, Lara F, Beltrán-Ortega A. [Available resources for the treatment of breast cancer in Mexico]. Salud Publica Mex. 2009;51 Suppl 2:s263-9.
Liedke PE, Finkelstein DM, Szymonifka J, et al. Outcomes of breast cancer in Brazil related to health care coverage: a retrospective cohort study. Cancer Epidemiol Biomarkers Prev. 2014;23:126-133. doi:10.1158/1055- 9965.epi-13-0693
9. Wong MCS, Lao XQ, Ho K-F, Goggins WB, Tse SLA. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. 2017;7(1):14300. doi:10.1038/s41598-017-14513-7
10. Ospina M ML. Observatorio Nacional de Cáncer Colombia. Rev Fac Nac Salud Pública. 2015;33(2). doi:10.17533/udea.rfnsp.v33n2a13
11. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. doi:10.3322/caac.21590
12. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4(2):e4439-e4439. doi:10.1371/journal.pone.0004439
13. Bradley CJ, Yabroff KR, Mariotto AB, Zeruto C, Tran Q, Warren JL. Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011). J Clin Oncol. 2017;35:529-535. doi:10.1200/jco.2016.69.4166
14. Fanelli S, Salvatore FP, De Pascale G, Faccilongo N. Insights for the future of health system partnerships in low- and middle-income countries: a systematic literature review. BMC Health Serv Res. 2020;20(1):571. doi:10.1186/s12913-020-05435-8
15. Arunachalam A, Li H, Bittoni MA, et al. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non Small-Cell Lung Cancer. Clin Lung Cancer. 2018;19:e783-e799. doi:10.1016/j.cllc.2018.05.016
16. Evans WK, Will BP, Berthelot JM, Earle CC. Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol. 1997;15:3038-3048. doi:10.1200/jco.1997.15.9.3038
17. Farjah F, Wood DE, Varghese TK, Massarweh NN, Symons RG, Flum DR. Health care utilization among surgically treated Medicare beneficiaries with lung cancer. Ann Thorac Surg. 2009;88:1749-1756. doi:10.1016/j.athoracsur.2009.08.006
18. Fleming I, Monaghan P, Gavin A, O’Neill C. Factors influencing hospital costs of lung cancer patients in Northern Ireland. Eur J Heal Econ. 2008;9:79-86. doi:10.1007/s10198-007-0047-4
19. Cipriano LE, Romanus D, Earle CC, et al. Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value Heal. 2011;14:41-52. doi:10.1016/j.jval.2010.10.006
20. Keusters WR, de Weger VA, Hövels A, Schellens JHM, Frederix GWJ. Changing costs of metastatic non small cell lung cancer in the Netherlands. Lung Cancer. 2017;114:56-61. doi:10.1016/j.lungcan.2017.10.005
21. Verleger K, Penrod JR, Manley Daumont M, et al. Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe. Clin Outcomes Res. 2020;12:23-33. doi:10.2147/ceor.s223760
22. Bloom DE, Cafiero E, Jané-Llopis E, et al. The Global Economic Burden of Noncommunicable Diseases. Program on the Global Demography of Aging; 2012.
23. Unit EI. Breakaway: The global burden of cancer-challenges and opportunities. Econ. 2009.
24. Ghebreyesus TA. Acting on NCDs: counting the cost. Lancet. 2018;391(10134):1973-1974. doi:10.1016/S0140-6736(18)30675-5
25. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy (New York). 2006;77:51-63. doi:10.1016/j.healthpol.2005.07.016
26. Robinson LA, Hammitt JK. Research Synthesis and the Value per Statistical Life. Risk Anal. 2015;35:1086-1100. doi:10.1111/risa.12366
27. Amin AP, McNeely C, Spertus JA, et al. Incremental Cost of Acute Kidney Injury after Percutaneous Coronary Intervention in the United States. Am J Cardiol. 2020;125(1):29-33. doi:10.1016/j.amjcard.2019.09.042
28. Raez LE, Cardona AF, Santos ES, et al. The burden of lung cancer in Latin- America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. Lung Cancer. 2018;119:7-13. doi:10.1016/j.lungcan.2018.02.014
29. Jeon SM, Kwon JW, Choi SH, Park HY. Economic burden of lung cancer: A retrospective cohort study in South Korea, 2002-2015. PLoS One. 2019;14(2):2002-2015. doi:10.1371/journal.pone.0212878
30. Prada SI, Perez AM, Nieto-Aristizábal I, Tobón GJ. Direct cost of lupus care in the developing world: the case of Colombia. Lupus. 2019;28(8):970-976. doi:10.1177/0961203319856093
31. Lee YR, Cho B, Jo MW, et al. Measuring the economic burden of disease and injury in Korea, 2015. J Korean Med Sci. 2019;34:1-11.
32. Rice DP. Cost of illness studies: what is good about them? Inj Prev. 2000;6:177-179. doi:10.1136/ip.6.3.177
33. Pichon-Riviere A, Alcaraz A, Palacios A, et al. The health and economic burden of smoking in 12 Latin American countries and the potential effect of increasing tobacco taxes: an economic modelling study. Lancet Glob Heal. 2020;8(10):e1282-e1294. doi:10.1016/S2214-109X(20)30311-9
34. Choi H-J, Lee E-W. Methodology of Estimating Socioeconomic Burden of Disease Using National Health Insurance (NHI) Data. In: Evaluation of Health Services. ; 2019:1-17.
35. Ghosh K, Bondarenko I, Messer KL, et al. Attributing medical spending to conditions: A comparison of methods. PLoS One. 2020;15(8 August):1-17. doi:10.1371/journal.pone.0237082
36. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual Medical Spending Attributable To Obesity: Payer-And Service-Specific Estimates. Health Aff. 2009;28(Supplement 1):w822-w831. doi:10.1377/hlthaff.28.5.w822
37. Roberts RR, Scott RDII, Hota B, et al. Costs Attributable to Healthcare- Acquired Infection in Hospitalized Adults and a Comparison of Economic Methods. Med Care. 2010;48(11). https://journals.lww.com/lwwmedicalcare/ Fulltext/2010/11000/Costs_Attributable_to_Healthcare_Acquire d.12.aspx.
38. Pagano E, Petrelli A, Picariello R, Merletti F, Gnavi R, Bruno G. Is the choice of the statistical model relevant in the cost estimation of patients with chronic diseases? An empirical approach by the Piedmont Diabetes Registry. BMC Health Serv Res. 2015;15(1):1-7. doi:10.1186/s12913-015- 1241-1
39. Zhao Q-Y, Luo J-C, Su Y, Zhang Y-J, Tu G-W, Luo Z. Propensity score matching with R: conventional methods and new features. Ann Transl Med. 2021;9(9):812-812. doi:10.21037/atm-20-3998
40. Xie L, Vaidya N, Xin K, et al. Evaluating The Economic Burden and Health Care Utilization of Lung Cancer in The Us Medicare Population. Value Heal. 2016;19(7):A726. doi:10.1016/j.jval.2016.09.2173
41. Elze MC, Gregson J, Baber U, et al. Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. J Am Coll Cardiol. 2017;69(3):345-357. doi:10.1016/j.jacc.2016.10.060
42. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424. doi:10.1080/00273171.2011.568786
43. Austin PC. Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf. 2008;17(12):1218-1225. doi:10.1002/pds.1674
44. Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Mak an Int J Soc Med Decis Mak. 2009;29(6):661-677. doi:10.1177/0272989X09341755
45. Morgan SL, Todd JJ. 6. A Diagnostic Routine for the Detection of Consequential Heterogeneity of Causal Effects. Sociol Methodol. 2008;38(1):231-282. doi:10.1111/j.1467-9531.2008.00204.x
46. Austin PC. Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score. Pharmacoepidemiol Drug Saf. 2008;17(12):1202-1217.
47. Imai K, King G, Stuart E. Misunderstandings Among Experimentalists and Observationalists about Causal Inference. J R Stat Soc Ser A. 2008;171, part:481{\textendash}502.
48. Hagen T. Econometric Evaluation of a Placement Coaching Program for Recipients of Disability Insurance Benefits in Switzerland Working Paper Series: Business and Law Econometric Evaluation of a Placement Coaching Program for Recipients of Disability Insurance Bene. 2016.
49. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
50. Gardner M, Shepperd S, Godfrey M, et al. A retrospective propensity score matched analysis, using administrative data, of alternatives to hospital admission for older people. 2019. https://www.ncbi.nlm.nih.gov/books/NBK538039/. Accessed August 11, 2021.
51. Rubin DB. Using propensity scores to help design observational studies: Application to the tobacco litigation. Matched Sampl Causal Eff. 2001:365- 382. doi:10.1017/CBO9780511810725.030
52. Taber DJ, Gebregziabher M, Payne EH, Srinivas T, Baliga PK, Egede LE. Overall Graft Loss Versus Death-Censored Graft Loss: Unmasking the Magnitude of Racial Disparities in Outcomes among US Kidney Transplant Recipients. Transplantation. 2017;101(2):402-410. doi:10.1097/TP.0000000000001119
53. Sheldon TA. Estimating treatment effects: real or the result of chance? Evid Based Nurs. 2000;3(2):36 LP - 39. doi:10.1136/ebn.3.2.36
54. Schafer JL, Kang J. Average causal effects from nonrandomized studies: a practical guide and simulated example. Psychol Methods. 2008;13(4):279- 313. doi:10.1037/a0014268
55. Abadie A, Imbens GW. Large sample properties of matching estimators for average treatment effects. Econometrica. 2006;74(1):235-267. doi:10.1111/j.1468-0262.2006.00655.x
56. Austin PC. Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples. Stat Med. 2011;30(11):1292-1301. doi:10.1002/sim.4200
57. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013;32(16):2837-2849. doi:10.1002/sim.5705
58. Gayat E, Resche-Rigon M, Mary J-Y, Porcher R. Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study. Pharm Stat. 2012;11(3):222-229. doi:10.1002/pst.537
59. Dash S, Shakyawar SK, Sharma M, Kaushik S. Big data in healthcare: management, analysis and future prospects. J Big Data. 2019;6(1). doi:10.1186/s40537-019-0217-0
60. Ehrenstein V, Nielsen H, Pedersen AB, Johnsen SP, Pedersen L. Clinical epidemiology in the era of big data: new opportunities, familiar challenges. Clin Epidemiol. 2017;Volume 9(4):245-250. doi:10.2147/CLEP.S129779
61. Center for disease Control and Prevention (CDC). Administrative Claims Databases. https://www.cdc.gov/visionhealth/vehss/data/claims/index.html. Published 2020. Accessed August 5, 2021.
62. Shih Y-CT, Liu L. Use of Claims Data for Cost and Cost-Effectiveness Research. Semin Radiat Oncol. 2019;29(4):348-353. doi:10.1016/j.semradonc.2019.05.009
63. Riley GF. Administrative and claims records as sources of health care cost data. Med Care. 2009;47(7 Suppl 1):S51-5. doi:10.1097/MLR.0b013e31819c95aa
64. Rosen AB, Cutler DM. Challenges in building disease-based national health accounts. Med Care. 2009;47:S7-13. doi:10.1097/MLR.0b013e3181a23e12
65. Rizzo JA, Chen J, Gunnarsson CL, Naim A, Lofland JH. Adjusting for comorbidities in cost of illness studies. J Med Econ. 2015;18:12-28. doi:10.3111/13696998.2014.969434
66. Lee DW, Meyer JW, Clouse J. Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective. Value Heal. 2001;4:329-334. doi:10.1046/j.1524-4733.2001.44012.x
67. Piñeros M, Abriata MG, Vries E, et al. Progress, challenges and ways forward supporting cancer surveillance in Latin America. Int J Cancer. 2020;(June):1-9. doi:10.1002/ijc.33407
68. Gomes AL, Turbay T, Venturella P, Cecagno L, Johnson G, Caleffi M. Cancer Diagnosis and Treatment: The Need for Compulsory Registration. J Glob Oncol. 2018;4(Supplement 2):153s-153s. doi:10.1200/jgo.18.70800
69. Lengerich EJ, Siedlecki JC, Brownson R, et al. Mentorship and competencies for applied chronic disease epidemiology. J Public Health Manag Pract. 2003;9(4):275-283. doi:10.1097/00124784-200307000-00005
70. Bray F, Colombet M, Mery L, Piñeros M, Znaor A ZR and FJ. CancerIncidence in Five Continents. (International Agency for Research on Cancer., ed.). Lyon; 2017.
71. Bertram MY, Sweeny K, Lauer JA, et al. Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services. Lancet. 2018;391(10134):2071-2078. doi:10.1016/S0140-6736(18)30665-2
72. Fletcher R, Fletcher S. Risk: Looking Forward. In: Clinical Epidemiology The Essentials. Fourth edi. ; 2005:75-91.
73. Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005;50(2):143-154. doi:10.1016/j.lungcan.2005.06.005
74. Buitrago G, Amaya-Nieto J, Torres GF. Prevalence of lung cancer in Colombia and a new diagnostic algorithm using health administrative databases: A real-world evidence study. J Clin Oncol. 2021;39(S15):e18764.
75. Ministerio de salud y protección social de Colombia. Estudio de Suficiencia y de Los Mecanismos de Ajuste Del Riesgo Para El Cálculo de La Unidad de Pago Por Capitación, Recursos Para Garantizar La Financiación de Tecnologías En Salud y Servicios En Los Regímenes Contributivo y Subsidiado. Año 2020. Bogotá D.C.; 2019.
76. Mazzali C, Paganoni AM, Ieva F, et al. Methodological issues on the use of administrative data in healthcare research: the case of heart failure hospitalizations in Lombardy region, 2000 to 2012. BMC Health Serv Res. 2016;16(1):234. doi:10.1186/s12913-016-1489-0
77. Boulton C, Wilkinson JM. Use of public datasets in the examination of multimorbidity: Opportunities and challenges. Mech Ageing Dev. 2020;190:111310. doi:https://doi.org/10.1016/j.mad.2020.111310
78. Andrillon A, Pirracchio R, Chevret S. Performance of propensity score matching to estimate causal effects in small samples. Stat Methods Med Res. 2020;29(3):644-658. doi:10.1177/0962280219887196
79. Champely S. Pwr: Basic Functions for Power Analysis.; 2020. https://cran.rproject. org/package=pwr.
80. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd Edition) 2nd Edition. Lauwerence.; 1988.
81. Cuenta de alto costo. Situación Del Cáncer En La Población Adulta Atendida En El SGSSS de Colombia 2018. Bogotá D.C.; 2018.
82. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288-1294. doi:10.1016/j.jclinepi.2004.03.012
83. Williamson EJ, Forbes A. Introduction to propensity scores. Respirology. 2014;19(5):625-635. doi:https://doi.org/10.1111/resp.12312
84. Halpern EF. Behind the Numbers: Inverse Probability Weighting. Radiology. 2014;271(3):625-628. doi:10.1148/radiol.14140035
85. Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health. 2010;13(2):273-277. doi:10.1111/j.1524-4733.2009.00671.x
86. Chesnaye NC, Stel VS, Tripepi G, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1):14-20. doi:10.1093/ckj/sfab158
87. Allan V, Ramagopalan S V., Mardekian J, et al. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. J Comp Eff Res. 2020;9(9):603-614. doi:10.2217/cer-2020-0013
88. Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics. 1968;24(2):295-313.
89. Rosenbaum PR, Rubin DB. Reducing Bias in Observational Studies Using Subclassification on the Propensity Score. J Am Stat Assoc. 1984;79(387):516-524. doi:10.1080/01621459.1984.10478078
90. Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. Commun Stat - Simul Comput. 2009;38(6):1228-1234. doi:10.1080/03610910902859574
91. Wooldridge JM. Introductory Econometrics: A Modern Approach. Cengage learning; 2015.
92. Rubin DB. Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation. Heal Serv Outcomes Res Methodol 2001 23. 2001;2(3):169-188. doi:10.1023/A:1020363010465
93. Leuven E, Sianesi B. “PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing.” 2003.
94. Thomson S, Foubister T, Figueras J, Kutzin J, Permant G, Bryndova L. Addressing Financial Sustainability in Health Systems.; 2009. https://www.euro.who.int/__data/assets/pdf_file/0018/76041/E93058.pdf.
95. Gregori D, Petrinco M, Bo S, Desideri A, Merletti F, Pagano E. Regression models for analyzing costs and their determinants in health care: an introductory review. Int J Qual Heal Care. 2011;23(3):331-341. doi:10.1093/INTQHC/MZR010
96. Kim S, Park SJ, Byun SJ, Park KH, Suh HS. Incremental economic burden associated with exudative age-related macular degeneration: a populationbased study. BMC Health Serv Res. 2019;19(1):1-10. doi:10.1186/s12913- 019-4666-0
97. Castro-Villarreal S, Beltran-Ostos A, Valencia CF. Estimation of Prevalence and Incremental Costs of Systemic Lupus Erythematosus in a Middle- Income Country Using Machine Learning on Administrative Health Data. Value Heal Reg Issues. 2021;26:98-104. doi:10.1016/j.vhri.2021.04.005
98. Cai Y, Chen W, Wang X, et al. Contemporary trends on expenditure of hospital care on total cancer and its subtypes in China during 2008−2017. Chinese J Cancer Res. 2021;33(5):627-636. doi:10.21147/j.issn.1000- 9604.2021.05.09
99. Liu W, Tao Z-W, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020;133(9):1032-1038. doi:10.1097/CM9.0000000000000775
100. Gouliaev A, Risikesan J, Christensen NL, et al. Direct and indirect economic burden of lung cancer in Denmark a nationwide study. Eur Clin Respir J. 2021;8(1). doi:10.1080/20018525.2021.1951963
101. Cicin I, Oksuz E, Karadurmus N, et al. Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective. Health Econ Rev. 2021;11(1):1-12. doi:10.1186/s13561-021-00322-2
102. Granger E, Watkins T, Sergeant JC, Lunt M. A review of the use of propensity score diagnostics in papers published in high-ranking medical journals. BMC Med Res Methodol. 2020;20(1):1-9. doi:10.1186/s12874-020- 00994-0
103. Crown WH. Propensity-score matching in economic analyses: Comparison with regression models, instrumental variables, residual inclusion, differences-in-differences, and decomposition methods. Appl Health Econ Health Policy. 2014;12(1):7-18. doi:10.1007/s40258-013-0075-4
104. Ciminata G, Geue C, Wu O, Deidda M, Kreif N, Langhorne P. Propensity score methods for comparative-effectiveness analysis: A case study of direct oral anticoagulants in the atrial fibrillation population. PLoS One. 2022;17(1 1):1-14. doi:10.1371/journal.pone.0262293
105. Austin PC, Stuart EA. The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes. Stat Methods Med Res. 2017;26(4):1654-1670. doi:10.1177/0962280215584401
106. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228-1234. doi:10.1080/03610910902859574
107. Austin PC, Mamdani MM. A comparison of propensity score methods: acase-study estimating the effectiveness of post-AMI statin use. Stat Med. 2006;25(12):2084-2106. doi:10.1002/sim.2328
108. Austin PC, Xin Yu AY, Vyas M V., Kapral MK. Applying Propensity Score Methods in Clinical Research in Neurology. Neurology. 2021;97(18):856- 863. doi:10.1212/WNL.0000000000012777
109. Bugge C, Sæther EM, Brustugun OT, Kristiansen IS. Societal cost of cancer in Norway –Results of taking a broader cost perspective. Health Policy (New York). 2021;125(8):1100-1107. doi:10.1016/j.healthpol.2021.05.008
110. Awano N, Izumo T, Inomata M, et al. Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis. Jpn J Clin Oncol. 2021;51(5):778-785. doi:10.1093/jjco/hyaa258
111. Buja A, Rivera M, De Polo A, et al. Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model. Thorac Cancer. 2021;12(1):13-20. doi:10.1111/1759- 7714.13616
112. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004;23(19):2937-2960. doi:10.1002/SIM.1903
113. The Economist. EL CÁNCER DE PULMÓN EN AMÉRICA LATINA : Es tiempo de dejar de mirar hacia otro lado. 2018:67. http://www.vi-da.cl/wpcontent/ uploads/2018/09/EIU_Roche-Lung-cancer-in-Latin-America_Timeto- stop-looking-away_Español.pdf.
114. Pérez N, Murillo R, Pinzón C, Hernández G. Costos de la atención médica del cáncer de pulmón, la EPOC y el IAM atribuibles al consumo de tabaco en Colombia (proyecto multicéntrico de la OPS). Rev colomb cancerol. 2007:241-249.
115. Rossel J, Rousson V, Eggli Y. A comparison of statistical methods for allocating disease costs in the presence of interactions. Stat Med. 2021;(May 2020):1-13. doi:10.1002/sim.8950
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.license.spa.fl_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv xvii, 132 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Universidad Nacional de Colombia
dc.publisher.program.spa.fl_str_mv Bogotá - Medicina - Maestría en Epidemiología Clínica
dc.publisher.faculty.spa.fl_str_mv Facultad de Medicina
dc.publisher.place.spa.fl_str_mv Bogotá, Colombia
dc.publisher.branch.spa.fl_str_mv Universidad Nacional de Colombia - Sede Bogotá
institution Universidad Nacional de Colombia
bitstream.url.fl_str_mv https://repositorio.unal.edu.co/bitstream/unal/86518/1/license.txt
https://repositorio.unal.edu.co/bitstream/unal/86518/2/1015402427.2023.pdf
bitstream.checksum.fl_str_mv eb34b1cf90b7e1103fc9dfd26be24b4a
27affda0dccac99a21bfb24197a9eeac
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad Nacional de Colombia
repository.mail.fl_str_mv repositorio_nal@unal.edu.co
_version_ 1806886119529250816
spelling Atribución-NoComercial-SinDerivadas 4.0 Internacionalinfo:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Buitrago Gutiérrez, Giancarloc304fd7c64c44ef2ca0d627075cbb8cfAmaya Nieto, Javier Antonio8e89a5d86b6127e9edd69b2629291c71Servicios y sistemas de saludAmaya Nieto, Javier Antonio [000-0002-9856-6242]https://www.researchgate.net/profile/Javier-Amaya-NietoAmaya Nieto, Javier Antonio [a0ZnRskAAAAJ&hl]2024-07-17T14:35:44Z2024-07-17T14:35:44Z2022https://repositorio.unal.edu.co/handle/unal/86518Universidad Nacional de ColombiaRepositorio Institucional Universidad Nacional de Colombiahttps://repositorio.unal.edu.co/Ilustraciones, diagramas, mapasIntroducción: el cáncer de pulmón (CP) es una de las enfermedades más mortales en el mundo. La atención en salud de pacientes con esta enfermedad ha sido asociada a un costo más elevado que el de otras enfermedades y otros tipos de cáncer. En Colombia y otros países latinoamericanos, es necesario desarrollar estudios que investiguen el CP desde el punto de vista económico. Objetivos: estimar el costo incremental derivado de la atención de pacientes con diagnóstico de cáncer de pulmón afiliados al régimen contributivo desde la perspectiva del sistema de salud colombiano para el año 2017 y comparar el rendimiento de diferentes métodos estadísticos para la estimación del costo incremental de la enfermedad que usan puntajes de propensión. Metodología: estudio observacional analítico de cohorte histórica realizado con información de bases de datos administrativas. El costo incremental derivado de la atención de pacientes se estimó utilizando una aproximación de casos prevalentes y tomando a los pacientes sin CP como grupo de no expuestos. Para el análisis se utilizaron tres métodos de estimación: emparejamiento con puntajes de propensión (PSM), ponderación de la probabilidad inversa (IPW) y estratificación con puntajes de propensión. Resultados: La cohorte utilizada incluyó 13 301 865 sujetos. La media de edad fue 46,2 años (DE = 14,72) y el 58,2% de los pacientes eran hombres. Para los modelos de IPW, PSM y estratificación con puntajes de propensión se incluyeron 13 190 409, 5 340 y 13 301 865 sujetos y se alcanzaron diferencias estandarizadas. (Texto tomado de la fuente)Introduction: Lung cancer is one of the deadliest diseases in the region and in the world. It has also been associated with a high health cost compared to other diseases and other types of cancer. In Colombia and Latin American countries there is a need to develop studies that address this condition from the economic point of view. Objective: to estimate the incremental cost derived from the healthcare of patients diagnosed with lung cancer affiliated to the contributory regime from the perspective of the Colombian health system for 2017. This project also aims to compare various types of statistical analyzes that use methods of propensity score and to compare its performance for estimating incremental health cost. Methods: Analytical observational study of historical cohort that used administrative databases to identify the incremental cost during the year 2017, derived from the care of patients with lung cancer using an approach of prevalent cases and using as nonexposed group those patients without lung cancer. Three different approaches were used for the analysis: (i) matching with propensity scores; ii) stratification with propensity scores and iii) inverse probability weighting. Results: Total cohort included was 13 301 865 people. The mean age was 46.2 years (SD=14.72) and 58.2% were men. A total of 13 190 409, 5 340 and 13 301 865 people were used for the models of IPW, PSM and propensity score stratification, and standardized differences.MaestríaMagíster en epidemiología clínicaxvii, 132 páginasapplication/pdfspaUniversidad Nacional de ColombiaBogotá - Medicina - Maestría en Epidemiología ClínicaFacultad de MedicinaBogotá, ColombiaUniversidad Nacional de Colombia - Sede Bogotá610 - Medicina y saludNeoplasias PulmonaresSistemas de SaludLung NeoplasmsHealth SystemsCostos de la saludCáncer de pulmónPuntaje de propensiónCosto incrementalLung CancerPropensity ScoreIncremental Cost of IllnessImpacto del diagnóstico de cáncer de pulmón en los costos del sistema de salud en Colombia: comparación de tres métodos de estimación basados en puntajes de propensiónImpact of Lung Cancer Diagnosis on Health System Costs in Colombia: Comparison of Three Estimation Methods Based on Propensity ScoresTrabajo de grado - Maestríainfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/acceptedVersionTexthttp://purl.org/redcol/resource_type/TM1. Goss PE, Lee BL, Badovinac-Crnjevic T, et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013;14:391-436. doi:10.1016/s1470-2045(13)70048-22. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a populationbased study. Lancet Oncol. 2012;13(8):790-801. doi:https://doi.org/10.1016/S1470-2045(12)70211-53. Sierra MS, Soerjomataram I, Antoni S, et al. Cancer patterns and trends in Central and South America. Cancer Epidemiol. 2016;44:S23-S42. doi:10.1016/j.canep.2016.07.0134. Gilchrist SC, Howard VJ, Akinyemiju T, et al. Association of Sedentary Behavior with Cancer Mortality in Middle-aged and Older US Adults. JAMA Oncol. 2020;6(8):1210-1217. doi:10.1001/jamaoncol.2020.20455. Weintraub WS. The Economic Burden of Illness. JAMA Netw Open. 2023;6(3):e232663-e232663. doi:10.1001/jamanetworkopen.2023.26636. Organization IA for R on C-WH. Global Cancer Observatory. 2020. https://gco.iarc.fr/.7. Mohar A, Bargalló E, Ramírez MT, Lara F, Beltrán-Ortega A. [Available resources for the treatment of breast cancer in Mexico]. Salud Publica Mex. 2009;51 Suppl 2:s263-9.Liedke PE, Finkelstein DM, Szymonifka J, et al. Outcomes of breast cancer in Brazil related to health care coverage: a retrospective cohort study. Cancer Epidemiol Biomarkers Prev. 2014;23:126-133. doi:10.1158/1055- 9965.epi-13-06939. Wong MCS, Lao XQ, Ho K-F, Goggins WB, Tse SLA. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. 2017;7(1):14300. doi:10.1038/s41598-017-14513-710. Ospina M ML. Observatorio Nacional de Cáncer Colombia. Rev Fac Nac Salud Pública. 2015;33(2). doi:10.17533/udea.rfnsp.v33n2a1311. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. doi:10.3322/caac.2159012. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4(2):e4439-e4439. doi:10.1371/journal.pone.000443913. Bradley CJ, Yabroff KR, Mariotto AB, Zeruto C, Tran Q, Warren JL. Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011). J Clin Oncol. 2017;35:529-535. doi:10.1200/jco.2016.69.416614. Fanelli S, Salvatore FP, De Pascale G, Faccilongo N. Insights for the future of health system partnerships in low- and middle-income countries: a systematic literature review. BMC Health Serv Res. 2020;20(1):571. doi:10.1186/s12913-020-05435-815. Arunachalam A, Li H, Bittoni MA, et al. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non Small-Cell Lung Cancer. Clin Lung Cancer. 2018;19:e783-e799. doi:10.1016/j.cllc.2018.05.01616. Evans WK, Will BP, Berthelot JM, Earle CC. Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol. 1997;15:3038-3048. doi:10.1200/jco.1997.15.9.303817. Farjah F, Wood DE, Varghese TK, Massarweh NN, Symons RG, Flum DR. Health care utilization among surgically treated Medicare beneficiaries with lung cancer. Ann Thorac Surg. 2009;88:1749-1756. doi:10.1016/j.athoracsur.2009.08.00618. Fleming I, Monaghan P, Gavin A, O’Neill C. Factors influencing hospital costs of lung cancer patients in Northern Ireland. Eur J Heal Econ. 2008;9:79-86. doi:10.1007/s10198-007-0047-419. Cipriano LE, Romanus D, Earle CC, et al. Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value Heal. 2011;14:41-52. doi:10.1016/j.jval.2010.10.00620. Keusters WR, de Weger VA, Hövels A, Schellens JHM, Frederix GWJ. Changing costs of metastatic non small cell lung cancer in the Netherlands. Lung Cancer. 2017;114:56-61. doi:10.1016/j.lungcan.2017.10.00521. Verleger K, Penrod JR, Manley Daumont M, et al. Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe. Clin Outcomes Res. 2020;12:23-33. doi:10.2147/ceor.s22376022. Bloom DE, Cafiero E, Jané-Llopis E, et al. The Global Economic Burden of Noncommunicable Diseases. Program on the Global Demography of Aging; 2012.23. Unit EI. Breakaway: The global burden of cancer-challenges and opportunities. Econ. 2009.24. Ghebreyesus TA. Acting on NCDs: counting the cost. Lancet. 2018;391(10134):1973-1974. doi:10.1016/S0140-6736(18)30675-525. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy (New York). 2006;77:51-63. doi:10.1016/j.healthpol.2005.07.01626. Robinson LA, Hammitt JK. Research Synthesis and the Value per Statistical Life. Risk Anal. 2015;35:1086-1100. doi:10.1111/risa.1236627. Amin AP, McNeely C, Spertus JA, et al. Incremental Cost of Acute Kidney Injury after Percutaneous Coronary Intervention in the United States. Am J Cardiol. 2020;125(1):29-33. doi:10.1016/j.amjcard.2019.09.04228. Raez LE, Cardona AF, Santos ES, et al. The burden of lung cancer in Latin- America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. Lung Cancer. 2018;119:7-13. doi:10.1016/j.lungcan.2018.02.01429. Jeon SM, Kwon JW, Choi SH, Park HY. Economic burden of lung cancer: A retrospective cohort study in South Korea, 2002-2015. PLoS One. 2019;14(2):2002-2015. doi:10.1371/journal.pone.021287830. Prada SI, Perez AM, Nieto-Aristizábal I, Tobón GJ. Direct cost of lupus care in the developing world: the case of Colombia. Lupus. 2019;28(8):970-976. doi:10.1177/096120331985609331. Lee YR, Cho B, Jo MW, et al. Measuring the economic burden of disease and injury in Korea, 2015. J Korean Med Sci. 2019;34:1-11.32. Rice DP. Cost of illness studies: what is good about them? Inj Prev. 2000;6:177-179. doi:10.1136/ip.6.3.17733. Pichon-Riviere A, Alcaraz A, Palacios A, et al. The health and economic burden of smoking in 12 Latin American countries and the potential effect of increasing tobacco taxes: an economic modelling study. Lancet Glob Heal. 2020;8(10):e1282-e1294. doi:10.1016/S2214-109X(20)30311-934. Choi H-J, Lee E-W. Methodology of Estimating Socioeconomic Burden of Disease Using National Health Insurance (NHI) Data. In: Evaluation of Health Services. ; 2019:1-17.35. Ghosh K, Bondarenko I, Messer KL, et al. Attributing medical spending to conditions: A comparison of methods. PLoS One. 2020;15(8 August):1-17. doi:10.1371/journal.pone.023708236. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual Medical Spending Attributable To Obesity: Payer-And Service-Specific Estimates. Health Aff. 2009;28(Supplement 1):w822-w831. doi:10.1377/hlthaff.28.5.w82237. Roberts RR, Scott RDII, Hota B, et al. Costs Attributable to Healthcare- Acquired Infection in Hospitalized Adults and a Comparison of Economic Methods. Med Care. 2010;48(11). https://journals.lww.com/lwwmedicalcare/ Fulltext/2010/11000/Costs_Attributable_to_Healthcare_Acquire d.12.aspx.38. Pagano E, Petrelli A, Picariello R, Merletti F, Gnavi R, Bruno G. Is the choice of the statistical model relevant in the cost estimation of patients with chronic diseases? An empirical approach by the Piedmont Diabetes Registry. BMC Health Serv Res. 2015;15(1):1-7. doi:10.1186/s12913-015- 1241-139. Zhao Q-Y, Luo J-C, Su Y, Zhang Y-J, Tu G-W, Luo Z. Propensity score matching with R: conventional methods and new features. Ann Transl Med. 2021;9(9):812-812. doi:10.21037/atm-20-399840. Xie L, Vaidya N, Xin K, et al. Evaluating The Economic Burden and Health Care Utilization of Lung Cancer in The Us Medicare Population. Value Heal. 2016;19(7):A726. doi:10.1016/j.jval.2016.09.217341. Elze MC, Gregson J, Baber U, et al. Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. J Am Coll Cardiol. 2017;69(3):345-357. doi:10.1016/j.jacc.2016.10.06042. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424. doi:10.1080/00273171.2011.56878643. Austin PC. Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf. 2008;17(12):1218-1225. doi:10.1002/pds.167444. Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Mak an Int J Soc Med Decis Mak. 2009;29(6):661-677. doi:10.1177/0272989X0934175545. Morgan SL, Todd JJ. 6. A Diagnostic Routine for the Detection of Consequential Heterogeneity of Causal Effects. Sociol Methodol. 2008;38(1):231-282. doi:10.1111/j.1467-9531.2008.00204.x46. Austin PC. Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score. Pharmacoepidemiol Drug Saf. 2008;17(12):1202-1217.47. Imai K, King G, Stuart E. Misunderstandings Among Experimentalists and Observationalists about Causal Inference. J R Stat Soc Ser A. 2008;171, part:481{\textendash}502.48. Hagen T. Econometric Evaluation of a Placement Coaching Program for Recipients of Disability Insurance Benefits in Switzerland Working Paper Series: Business and Law Econometric Evaluation of a Placement Coaching Program for Recipients of Disability Insurance Bene. 2016.49. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.50. Gardner M, Shepperd S, Godfrey M, et al. A retrospective propensity score matched analysis, using administrative data, of alternatives to hospital admission for older people. 2019. https://www.ncbi.nlm.nih.gov/books/NBK538039/. Accessed August 11, 2021.51. Rubin DB. Using propensity scores to help design observational studies: Application to the tobacco litigation. Matched Sampl Causal Eff. 2001:365- 382. doi:10.1017/CBO9780511810725.03052. Taber DJ, Gebregziabher M, Payne EH, Srinivas T, Baliga PK, Egede LE. Overall Graft Loss Versus Death-Censored Graft Loss: Unmasking the Magnitude of Racial Disparities in Outcomes among US Kidney Transplant Recipients. Transplantation. 2017;101(2):402-410. doi:10.1097/TP.000000000000111953. Sheldon TA. Estimating treatment effects: real or the result of chance? Evid Based Nurs. 2000;3(2):36 LP - 39. doi:10.1136/ebn.3.2.3654. Schafer JL, Kang J. Average causal effects from nonrandomized studies: a practical guide and simulated example. Psychol Methods. 2008;13(4):279- 313. doi:10.1037/a001426855. Abadie A, Imbens GW. Large sample properties of matching estimators for average treatment effects. Econometrica. 2006;74(1):235-267. doi:10.1111/j.1468-0262.2006.00655.x56. Austin PC. Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples. Stat Med. 2011;30(11):1292-1301. doi:10.1002/sim.420057. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013;32(16):2837-2849. doi:10.1002/sim.570558. Gayat E, Resche-Rigon M, Mary J-Y, Porcher R. Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study. Pharm Stat. 2012;11(3):222-229. doi:10.1002/pst.53759. Dash S, Shakyawar SK, Sharma M, Kaushik S. Big data in healthcare: management, analysis and future prospects. J Big Data. 2019;6(1). doi:10.1186/s40537-019-0217-060. Ehrenstein V, Nielsen H, Pedersen AB, Johnsen SP, Pedersen L. Clinical epidemiology in the era of big data: new opportunities, familiar challenges. Clin Epidemiol. 2017;Volume 9(4):245-250. doi:10.2147/CLEP.S12977961. Center for disease Control and Prevention (CDC). Administrative Claims Databases. https://www.cdc.gov/visionhealth/vehss/data/claims/index.html. Published 2020. Accessed August 5, 2021.62. Shih Y-CT, Liu L. Use of Claims Data for Cost and Cost-Effectiveness Research. Semin Radiat Oncol. 2019;29(4):348-353. doi:10.1016/j.semradonc.2019.05.00963. Riley GF. Administrative and claims records as sources of health care cost data. Med Care. 2009;47(7 Suppl 1):S51-5. doi:10.1097/MLR.0b013e31819c95aa64. Rosen AB, Cutler DM. Challenges in building disease-based national health accounts. Med Care. 2009;47:S7-13. doi:10.1097/MLR.0b013e3181a23e1265. Rizzo JA, Chen J, Gunnarsson CL, Naim A, Lofland JH. Adjusting for comorbidities in cost of illness studies. J Med Econ. 2015;18:12-28. doi:10.3111/13696998.2014.96943466. Lee DW, Meyer JW, Clouse J. Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective. Value Heal. 2001;4:329-334. doi:10.1046/j.1524-4733.2001.44012.x67. Piñeros M, Abriata MG, Vries E, et al. Progress, challenges and ways forward supporting cancer surveillance in Latin America. Int J Cancer. 2020;(June):1-9. doi:10.1002/ijc.3340768. Gomes AL, Turbay T, Venturella P, Cecagno L, Johnson G, Caleffi M. Cancer Diagnosis and Treatment: The Need for Compulsory Registration. J Glob Oncol. 2018;4(Supplement 2):153s-153s. doi:10.1200/jgo.18.7080069. Lengerich EJ, Siedlecki JC, Brownson R, et al. Mentorship and competencies for applied chronic disease epidemiology. J Public Health Manag Pract. 2003;9(4):275-283. doi:10.1097/00124784-200307000-0000570. Bray F, Colombet M, Mery L, Piñeros M, Znaor A ZR and FJ. CancerIncidence in Five Continents. (International Agency for Research on Cancer., ed.). Lyon; 2017.71. Bertram MY, Sweeny K, Lauer JA, et al. Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services. Lancet. 2018;391(10134):2071-2078. doi:10.1016/S0140-6736(18)30665-272. Fletcher R, Fletcher S. Risk: Looking Forward. In: Clinical Epidemiology The Essentials. Fourth edi. ; 2005:75-91.73. Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005;50(2):143-154. doi:10.1016/j.lungcan.2005.06.00574. Buitrago G, Amaya-Nieto J, Torres GF. Prevalence of lung cancer in Colombia and a new diagnostic algorithm using health administrative databases: A real-world evidence study. J Clin Oncol. 2021;39(S15):e18764.75. Ministerio de salud y protección social de Colombia. Estudio de Suficiencia y de Los Mecanismos de Ajuste Del Riesgo Para El Cálculo de La Unidad de Pago Por Capitación, Recursos Para Garantizar La Financiación de Tecnologías En Salud y Servicios En Los Regímenes Contributivo y Subsidiado. Año 2020. Bogotá D.C.; 2019.76. Mazzali C, Paganoni AM, Ieva F, et al. Methodological issues on the use of administrative data in healthcare research: the case of heart failure hospitalizations in Lombardy region, 2000 to 2012. BMC Health Serv Res. 2016;16(1):234. doi:10.1186/s12913-016-1489-077. Boulton C, Wilkinson JM. Use of public datasets in the examination of multimorbidity: Opportunities and challenges. Mech Ageing Dev. 2020;190:111310. doi:https://doi.org/10.1016/j.mad.2020.11131078. Andrillon A, Pirracchio R, Chevret S. Performance of propensity score matching to estimate causal effects in small samples. Stat Methods Med Res. 2020;29(3):644-658. doi:10.1177/096228021988719679. Champely S. Pwr: Basic Functions for Power Analysis.; 2020. https://cran.rproject. org/package=pwr.80. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd Edition) 2nd Edition. Lauwerence.; 1988.81. Cuenta de alto costo. Situación Del Cáncer En La Población Adulta Atendida En El SGSSS de Colombia 2018. Bogotá D.C.; 2018.82. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288-1294. doi:10.1016/j.jclinepi.2004.03.01283. Williamson EJ, Forbes A. Introduction to propensity scores. Respirology. 2014;19(5):625-635. doi:https://doi.org/10.1111/resp.1231284. Halpern EF. Behind the Numbers: Inverse Probability Weighting. Radiology. 2014;271(3):625-628. doi:10.1148/radiol.1414003585. Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health. 2010;13(2):273-277. doi:10.1111/j.1524-4733.2009.00671.x86. Chesnaye NC, Stel VS, Tripepi G, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1):14-20. doi:10.1093/ckj/sfab15887. Allan V, Ramagopalan S V., Mardekian J, et al. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. J Comp Eff Res. 2020;9(9):603-614. doi:10.2217/cer-2020-001388. Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics. 1968;24(2):295-313.89. Rosenbaum PR, Rubin DB. Reducing Bias in Observational Studies Using Subclassification on the Propensity Score. J Am Stat Assoc. 1984;79(387):516-524. doi:10.1080/01621459.1984.1047807890. Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. Commun Stat - Simul Comput. 2009;38(6):1228-1234. doi:10.1080/0361091090285957491. Wooldridge JM. Introductory Econometrics: A Modern Approach. Cengage learning; 2015.92. Rubin DB. Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation. Heal Serv Outcomes Res Methodol 2001 23. 2001;2(3):169-188. doi:10.1023/A:102036301046593. Leuven E, Sianesi B. “PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing.” 2003.94. Thomson S, Foubister T, Figueras J, Kutzin J, Permant G, Bryndova L. Addressing Financial Sustainability in Health Systems.; 2009. https://www.euro.who.int/__data/assets/pdf_file/0018/76041/E93058.pdf.95. Gregori D, Petrinco M, Bo S, Desideri A, Merletti F, Pagano E. Regression models for analyzing costs and their determinants in health care: an introductory review. Int J Qual Heal Care. 2011;23(3):331-341. doi:10.1093/INTQHC/MZR01096. Kim S, Park SJ, Byun SJ, Park KH, Suh HS. Incremental economic burden associated with exudative age-related macular degeneration: a populationbased study. BMC Health Serv Res. 2019;19(1):1-10. doi:10.1186/s12913- 019-4666-097. Castro-Villarreal S, Beltran-Ostos A, Valencia CF. Estimation of Prevalence and Incremental Costs of Systemic Lupus Erythematosus in a Middle- Income Country Using Machine Learning on Administrative Health Data. Value Heal Reg Issues. 2021;26:98-104. doi:10.1016/j.vhri.2021.04.00598. Cai Y, Chen W, Wang X, et al. Contemporary trends on expenditure of hospital care on total cancer and its subtypes in China during 2008−2017. Chinese J Cancer Res. 2021;33(5):627-636. doi:10.21147/j.issn.1000- 9604.2021.05.0999. Liu W, Tao Z-W, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020;133(9):1032-1038. doi:10.1097/CM9.0000000000000775100. Gouliaev A, Risikesan J, Christensen NL, et al. Direct and indirect economic burden of lung cancer in Denmark a nationwide study. Eur Clin Respir J. 2021;8(1). doi:10.1080/20018525.2021.1951963101. Cicin I, Oksuz E, Karadurmus N, et al. Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective. Health Econ Rev. 2021;11(1):1-12. doi:10.1186/s13561-021-00322-2102. Granger E, Watkins T, Sergeant JC, Lunt M. A review of the use of propensity score diagnostics in papers published in high-ranking medical journals. BMC Med Res Methodol. 2020;20(1):1-9. doi:10.1186/s12874-020- 00994-0103. Crown WH. Propensity-score matching in economic analyses: Comparison with regression models, instrumental variables, residual inclusion, differences-in-differences, and decomposition methods. Appl Health Econ Health Policy. 2014;12(1):7-18. doi:10.1007/s40258-013-0075-4104. Ciminata G, Geue C, Wu O, Deidda M, Kreif N, Langhorne P. Propensity score methods for comparative-effectiveness analysis: A case study of direct oral anticoagulants in the atrial fibrillation population. PLoS One. 2022;17(1 1):1-14. doi:10.1371/journal.pone.0262293105. Austin PC, Stuart EA. The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes. Stat Methods Med Res. 2017;26(4):1654-1670. doi:10.1177/0962280215584401106. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228-1234. doi:10.1080/03610910902859574107. Austin PC, Mamdani MM. A comparison of propensity score methods: acase-study estimating the effectiveness of post-AMI statin use. Stat Med. 2006;25(12):2084-2106. doi:10.1002/sim.2328108. Austin PC, Xin Yu AY, Vyas M V., Kapral MK. Applying Propensity Score Methods in Clinical Research in Neurology. Neurology. 2021;97(18):856- 863. doi:10.1212/WNL.0000000000012777109. Bugge C, Sæther EM, Brustugun OT, Kristiansen IS. Societal cost of cancer in Norway –Results of taking a broader cost perspective. Health Policy (New York). 2021;125(8):1100-1107. doi:10.1016/j.healthpol.2021.05.008110. Awano N, Izumo T, Inomata M, et al. Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis. Jpn J Clin Oncol. 2021;51(5):778-785. doi:10.1093/jjco/hyaa258111. Buja A, Rivera M, De Polo A, et al. Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model. Thorac Cancer. 2021;12(1):13-20. doi:10.1111/1759- 7714.13616112. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004;23(19):2937-2960. doi:10.1002/SIM.1903113. The Economist. EL CÁNCER DE PULMÓN EN AMÉRICA LATINA : Es tiempo de dejar de mirar hacia otro lado. 2018:67. http://www.vi-da.cl/wpcontent/ uploads/2018/09/EIU_Roche-Lung-cancer-in-Latin-America_Timeto- stop-looking-away_Español.pdf.114. Pérez N, Murillo R, Pinzón C, Hernández G. Costos de la atención médica del cáncer de pulmón, la EPOC y el IAM atribuibles al consumo de tabaco en Colombia (proyecto multicéntrico de la OPS). Rev colomb cancerol. 2007:241-249.115. Rossel J, Rousson V, Eggli Y. A comparison of statistical methods for allocating disease costs in the presence of interactions. Stat Med. 2021;(May 2020):1-13. doi:10.1002/sim.8950BibliotecariosEstudiantesInvestigadoresPúblico generalLICENSElicense.txtlicense.txttext/plain; charset=utf-85879https://repositorio.unal.edu.co/bitstream/unal/86518/1/license.txteb34b1cf90b7e1103fc9dfd26be24b4aMD51ORIGINAL1015402427.2023.pdf1015402427.2023.pdfTesis de Maestría de Epidemiología Clínicaapplication/pdf1642025https://repositorio.unal.edu.co/bitstream/unal/86518/2/1015402427.2023.pdf27affda0dccac99a21bfb24197a9eeacMD52unal/86518oai:repositorio.unal.edu.co:unal/865182024-07-17 09:37:22.089Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.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

Publicaciones similares